Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 2: 234 - 241

DOI: https://doi.org/10.19852/j.cnki.jtcm.20210220.001

Research Articles

Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine

  • Wenguang XIA ,
  • Chanjuan ZHENG ,
  • Jixian ZHANG ,
  • Min HUANG ,
  • Qinglin LI ,
  • Can DUAN ,
  • Zhengliang LI ,
  • Cunyu FAN ,
  • Yilong ZOU ,
  • Bo XU ,
  • Fengwen YANG ,
  • Qingquan LIU
Expand
  • 1 Rehabilitation Department, Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan 430000, China
    2 Respiratory Department, Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan 430000, China
    3 Endocrinology Department, Hubei P rovincial Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan 430000, China
    4 Traditional Chinese Medicine Department, Tianjin University of Traditional Chinese Medicine, Tianjin 300000, China
    5 Emergency Department, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100000, China
LIU Qingquan, Emergency Department, Beijing Hospital of tra ditional Chinese Medicine, Beijing 100010, China. hxyykfzx@163.com, Telephone: +86-13910055687

Received date: 2021-01-06

  Accepted date: 2021-02-19

  Online published: 2022-04-01

Supported by

National Key R&D Program “Public Security Risk Prevention and Control and Emergency Technology and Equipment” Key Special Project(2020YFC0841600);Hubei Provincial Department of Science and Technology, 2020 Hubei Province New Pneumonia Emergency Science and Technology Project(2020FCA027);Hubei Provincial Health Commission, 2021-2022 TCM Scientific Research Project Key Project(ZY2021Z003);Hubei Provincial Health Commission Key Support Projects from 2021 to 2022(WJ2021Z009);Hubei Provincial Department of Science and Technology, 2020 Hubei Province Key R&D Program Project(2020BCB012)

Fold

Abstract

OBJECTIVE: To investigate the clinical efficacy and safety of a diagnosis and treatment plan for moderate coronavirus disease 2019 (COVID-19) that integrates traditional Chinese (TCM) and western medicine.

METHODS: One hundred twenty patients with moderate COVID-19 were randomized 1∶2 to the control group (n = 40) and experimental group (n = 80). Both groups received conventional western medicine treatment, and the experimental group also received TCM decoction. Over a 2-week period from diagnosis, we observed the time to clinical recovery (TTCR), rate of improvement on lung computed tomography (CT) imaging, time to defervescence, cough remission time, hospital discharge rate, average hospitalization stay, modified Medical Research Council (mMRC) scale score, clinical cure rate, laboratory findings, incidence of progression to severe or critical disease, and adverse events.

RESULTS: Among 120 enrolled patients, 108 completed the study. The baseline data did not differ between the experimental and control groups (all P > 0.05). After treatment, the TTCR, rate of lung CT imaging improvement, time to defervescence, cough remission time, hospital discharge rate, average hospitalization stay (among discharged patients), mMRC scale score, clinical cure rate, and rates of normal values for laboratory findings were better in the experimental group than in the control group (P < 0.05 or < 0.01). The incidence of progression to severe or critical disease and the incidence of adverse events did not differ between the two groups (P > 0.05).

CONCLUSION: The diagnosis and treatment plan integrating Chinese and western medicine showed improved clinical efficacy compared with western medicine alone for patients with moderate COVID-19 and is worthy of clinical promotion and application.

Key words： COVID-19; SARS-CoV-2; integrative medicine; diagnosis and treatment plan

Cite this article

Wenguang XIA , Chanjuan ZHENG , Jixian ZHANG , Min HUANG , Qinglin LI , Can DUAN , Zhengliang LI , Cunyu FAN , Yilong ZOU , Bo XU , Fengwen YANG , Qingquan LIU . Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine[J]. Journal of Traditional Chinese Medicine, 2022 , 42(2) : 234 -241 . DOI: 10.19852/j.cnki.jtcm.20210220.001

References

1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207.
2. Phan LT, Nguyen TV, Luong QC, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020; 382: 872-4.
3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20.
4. Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens 2020; 9: 331.
5. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020, 14: 69-71.
6. National Health Commission of the People’s Republic of China. Diagnosis and treatment of New coronavirus pneumonia.(trial version 5). (in Chinese). Published February 4, 2020. Accessed February 20, 2020: screen 10-14. Available from URL: http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
7. National Health Commission of the People's Republic of China. Diagnosis and treatment of new coronavirus pneumonia. (trial version 6). (in Chinese). Published February 18, 2020. Accessed February 20, 2020: screen 8-15. Available from URL: news.sciencenet.cn/htmlnews/2020/2/435927.shtm.
8. Lau AC, So LK, Miu FP, et al. Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol. Respirology 2004; 9: 173-83.
9. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45-67.
10. Yang Y, Wang SC, Bai WJ, Li RL, Ai J. Evaluation by survival analysis on effect of Traditional Chinese Medicine in treating children with respiratory syncytial viral pneumonia of phlegm-heat blocking Fei syndrome. Chin J Integr Med 2009; 15: 95-100.
11. Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019; 380: 517-27.
12. Sandberg J, Johnson MJ, Currow DC, Ekström M. Validation of the dyspnea exertion scale of breathlessness in people with life-limiting illness. J Pain Symptom Manage 2018; 56: 430-5.e2.
13. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9.
14. Abo-Hagar HH, Abo-Elezz AAE, Mehrez M, et al. Diagnostic efficacy of serum amyloid a protein and soluble intercellular adhesion molecule 1 in pediatric ventilator-associated pneumonia. J Intensive Care Med 2019; 34: 503-10.
15. Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV. Current and future developments in the treatment of virus-induced hypercytokinemia. Future Med Chem 2017; 9: 169-78.
Options
Outlines

/

〈 〉